Hematopoietic stem cell mobilization with plerixafor in sickle cell disease

Haematologica

Volumn 103, Issue 5, 2018, Pages 749-750

  Hsieh, Matthew M ^a   Tisdale, John F ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; FILGRASTIM; HEMOGLOBIN S; HYDROXYUREA; PLERIXAFOR; GRANULOCYTE COLONY STIMULATING FACTOR;

APHERESIS; EDITORIAL; ERYTHROCYTE TRANSFUSION; GENE EDITING; GENE TRANSFER; HOSPITALIZATION; HUMAN; LEUKAPHERESIS; LEUKOCYTOSIS; SICKLE CELL ANEMIA; STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL;

ANEMIA, SICKLE CELL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS;

EID: 85046368824     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2018.190876     Document Type: Editorial

References (9)

1. Fitzhugh CD, Hsieh MM, Bolan CD, Saenz C, Tisdale JF. Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium? Cytotherapy. 2009;11(4):464-471.
2. Hematti P, Tuchman S, Larochelle A, Metzger ME, Donahue RE, Tisdale JF. Comparison of retroviral transduction efficiency in CD34+ cells derived from bone marrow versus G-CSF-mobilized or G-CSF plus stem cell factor-mobilized peripheral blood in nonhuman primates. Stem Cells. 2004;22(6):1062-1069.
3. Uchida N, Fujita A, Hsieh MM, et al. Bone marrow as a hematopoietic stem cell source for gene therapy in sickle cell disease: evidence from Rhesus and SCD patients. Hum Gene Ther Clin Dev. 2017;28(3):136-144.
4. Uchida N, Bonifacino A, Krouse AE, et al. Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor. Exp Hematol. 2011;39(7):795-805.
5. Kanter J, Walters MC, Hsieh MM, et al. Interim results from a phase I/II clinical study of lenitoglobin gene therapy for severe sickle cell disease. Blood. 2016;128(22):1176.
6. Leonard A, Bonifacino A, Dominical VM, et al. Bone marrow characterization in sickle cell disease: inflammation and stress erythropoiesis lead to suboptimal CD34 recovery compared to normal volunteer bone marrow. Blood. 2017;130(Suppl 1):966.
7. Boulad F, Shore T, van Besien K, et al. Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results. Haematologica. 2018;103(5):770-777.
8. Lagresle-Peyrou C, Lefrere F, Magrin E, et al. Plerixafor enables the safe, rapid, efficient mobilization of haematopoietic stem cells in sickle cell disease patients after exchange transfusion. Haematologica. 2018;103(5):778-786.
9. Pantin J, Purev E, Tian X, et al. Effect of high-dose plerixafor on CD34(+) cell mobilization in healthy stem cell donors: results of a randomized crossover trial. Haematologica. 2017;102(3):600-609.